Inhibitors of MALT1 protease, which dampen canonical NF-κB activity without completely blocking it, may be a more attractive option and have recently yielded promising results for treatment of B cell lymphoma and autoimmune disease (75–78). The gene discussed is MALT1; the disease is B-cell non-Hodgkin lymphoma.